How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,659 results for

Antibiotic Food Interactions

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

102. Guidelines of care for the management of primary cutaneous melanoma

the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors

2019 American Academy of Dermatology

103. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

that are in development or US Food and Drug Administration (FDA)-approved. • Sponsored research funding or investigator-initiated studies (with partial or full funding from pharmaceutical companies) on psoriasis disease state or psoriasis drugs that are in development or FDA-approved. If a potential conflict was noted, the WG member recused himself or herself from discussion and drafting of recommendations pertinent to the topic area of interest. Complete group consensus was obtained for draft recommendations. Areas (...) ) • Infliximab (FDA approval on September 27, 2006) • Adalimumab (FDA approval on January 22, 2008) • Certolizumab (FDA approval on May 27, 2018) • Ustekinumab (FDA approval on September 25, 2009) • Secukinumab (FDA approval on January 21, 2015) • Ixekizumab (FDA approval on March 22, 2016) • Brodalumab (FDA approval on February 15, 2017) • Guselkumab (FDA approval on July 13, 2017) • Tildrakizumab (FDA approval on March 21, 2018) • Risankizumab (FDA approval pending) FDA , US Food and Drug Administration

2019 American Academy of Dermatology

106. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights

Economic empowerment (e.g. housing, food security, ability to pay for health care) Social accountability Health services Access to justice Accountability Self-care for health and well-being Regulated quality products and interventionsxiii Executive summary SCOPE OF SELF-CARE INTERVENTIONS While self-care is important in all aspects of health, it is particularly important – and particularly challenging to manage – for populations negatively affected by gender, political, cultural and power dynamics

2019 World Health Organisation Guidelines

107. Contraceptive Choices for Young People

with a higher estrogen content. Co-cyprindiol (Dianette ® ) is indicated to treat severe acne that has not responded to oral antibiotics. In those with less severe symptoms it should be withdrawn 3-4 months after the condition has resolved. For women with known hyperandrogenism, longer use with specialist review may be warranted. Young people should be advised that the progestogen-only implant may be associated with improvement, worsening or onset of acne. Mood Changes and Depression Young people may (...) improve acne and thus can be considered in those who require contraception. Overall, few differences have been found between COC types in terms of their effectiveness for treating acne. 72 In the UK, co-cyprindiol (Dianette ® ) 73,74 should not be used solely for contraception and is licensed for treatment of severe acne that has not responded to oral antibiotics. Ideally it should be withdrawn 3–4 months after the condition has resolved. However, for women with known hyperandrogenism, longer use may

2019 Faculty of Sexual & Reproductive Healthcare

108. Reducing Acute Care Length of Stay in Newfoundland & Labrador

common (see Table 8) with variable implementation. Table 8: Elements of colorectal surgery Care Pathways, based on included evidence NLCAHR October 2017 | Reducing Acute Care Length of Stay in Newfoundland & Labrador 23 Elements that are more common and have a more standardized implementation method are assumed to play a more critical role in the effectiveness of the Care Pathway. The most common preoperative elements shared by the majority of studies were: ? Counselling (76%), ? Restriction of foods

2018 Newfoundland and Labrador Centre for Health Information

109. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. (PubMed)

participant data were excluded from the analysis. The trial was assessed as high risk of bias for selective outcome reporting, especially when reporting on the trial's post hoc subgroup of participants by chronic inhaled antibiotic use.The trial was sponsored by PTC Therapeutics Incorporated with grant support by the Cystic Fibrosis Foundation, the Food and Drug Administration's Office of Orphan Products Development and the National Institutes of Health (NIH).The trial reported no significant difference (...) a reduced rate of pulmonary exacerbation compared to those not receiving chronic inhaled tobramycin. This drug interaction was not anticipated and may affect the interpretation of the trial results.There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with cystic fibrosis with class I mutations. Future trials should carefully assess for adverse events, notably renal impairment and consider the possibility of drug interactions. Cross-over trials should

Full Text available with Trip Pro

2017 Cochrane

110. Appropriate care at the end of life

indications, e.g., Braga 1 refers to studies in which percentages of oncology patients that receive chemotherapy in the last month of their life vary between 8 and 50%; Albrecht et al. 2 found that 27% of hospice patients received an antibiotic during the last seven days of life, most without a documented infectious diagnosis; a Dutch study 3 found that 62% of physicians agreed that patients at the end of life are longer treated than desirable. In Belgium, Gielen et al. 4 found that 51% of patients (...) their reflections on a time and place that is best suited for them – no one needs to travel. In addition, since respondents write down their reflections on the forum, researchers do not need to spend time to transcribe the input provided. On the other hand, no real interactions take place, making it sometimes difficult to interpret the written quotes in a nuanced way. Yet, because of the practicalities, we decided to copy this procedure, but choose to organise separate online focus groups for relatives (n=2; 1

2018 Belgian Health Care Knowledge Centre

111. Asthma

update. Ciclesonide (Alvesco ® ) is no longer a black triangle product. Minor addition to text regarding drug interactions with theophylline. Issued in January 2010. December 2009 — minor update. Clenil Modulite ® (beclometasone CFC-free) is no longer a black triangle product. Prescription updated. Issued in December 2009. November 2009 — minor update. The Supporting evidence section on Symbicort Smart® has been reworded to make it clear that the data summarized are from a single Cochrane review (...) asthma in an adolescent. British Medical Journal. [ ] Stefan, M., Shieh, M-S., and Spitzer, K. (2019) Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids. JAMA Internal Medicine. [ ] Primary evidence NEJM (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. The New England Journal of Medicine. [ ] Biospace Inc. (2018) GSK announces long-term data on mepolizumab in patients with severe

2017 Prodigy

112. Antiocoagulation - oral

to include recommendations and supporting evidence on the place of self-testing and self-management of warfarin. Advice on the management of the drug interaction between selective serotonin reuptake inhibitors (SSRIs) and warfarin has also been added. July 2009 — updated to include target INRs and duration of treatment for all indications for warfarin. A change to the recommendation concerning management of potential drug interaction between warfarin and macrolide antibiotics has also been made. December (...) of interaction with vitamin K antagonists and changes in INR. October to November 2016 — reviewed. A literature search was conducted in October 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Information about edoxaban, a new anticoagulant has been added to this topic. Previous changes October 2015 — minor update. Based on an update to the manufacturer's Summary of Product Characteristics (SPC

2017 Prodigy

113. Enhancing Equitable Access to Assistive Technologies in Canada

) are classified as medical devices and are treated similarly to prescription drugs. To be offered for sale in Canada, assistive technologies are regulated at the federal level through the Therapeutic Products Directorate of Health Canada’s Health Products and Food Branch.(18; 19) • The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent not-for-profit organization that centralizes the review of health technologies and drugs, and provides recommendations to governments on new health

2017 McMaster Health Forum

114. Management of Valvular Heart Disease

, such as the ‘eyeball test’, but rather on a combination of different objective estimates. Several tools are available for assessing frailty. , , 3.4 Endocarditis prophylaxis Antibiotic prophylaxis should be considered for high-risk procedures in patients with prosthetic valves, including transcatheter valves, or with repairs using prosthetic material and those with previous episodes of infective endocarditis. Recommendations regarding dental and cutaneous hygiene and strict aseptic measures during any invasive (...) procedures are advised in this population. Antibiotic prophylaxis should be considered in dental procedures involving manipulation of the gingival or periapical region of the teeth or manipulation of the oral mucosa. 3.5 Prophylaxis for rheumatic fever Prevention of rheumatic heart disease should preferably be oriented towards preventing the first attack of acute rheumatic fever. Antibiotic treatment of group A Streptococcus sore throat is key in primary prevention. In patients with rheumatic heart

Full Text available with Trip Pro

2017 European Society of Cardiology

115. Use of patient-reported outcome and experience measures in patient care and policy

European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire EQ-5D EuroQol 5D FDA United States’ Food and Drug Administration GP General Practitioner HAS Haute Autorité de Santé 8 Patient-reported outcome and experience measures KCE Report 303 HCAHPS Hospital Consumer Assessment of Healthcare providers and Systems HIS Health Interview Survey HRQoL Health-related Quality of Life HTA Health Technology Assessment ICHOM International Consortium for Health Outcome Measurement (...) applied and advocated to capture what really matters to patients. [4] KCE Report 303 Patient-reported outcome and experience measures 11 Scope - lessons learned based on international initiatives In this report we explain what PROMs and PREMs are, why they can be relevant to patients, clinicians and policy makers and what the barriers and prerequisites are in case of implementation. The study was requested by the federal public service for health, food safety and environment. The rationale

2018 Belgian Health Care Knowledge Centre

116. Outcome Measures Framework: Information Model Report

of the OMR Governance 37 Scope of Responsibilities 37 Steering Committee 37 Clinical Advisory Committee 38 OMR Staff 39 Interactions Between the Steering Committee and Clinical Advisory Committee 40 OMR Data Management 41 Submissions to the OMR 41 Management of Data Entered Into the OMR 41 Governance Procedures 42 Transparency 42 v Inclusion/Exclusion Criteria 42 Clinical Equivalency 43 OMR Procedures 45 Submission of New Content 45 Content Submitted by OMR Committees 45 Review of Submitted Content 45

2018 Effective Health Care Program (AHRQ)

117. WHO recommendations: intrapartum care for a positive childbirth experience

, depending on a woman’s preferences. Recommended Manual techniques for pain management 22. Manual techniques, such as massage or application of warm packs, are recommended for healthy pregnant women requesting pain relief during labour, depending on a woman’s preferences. Recommended Pain relief for preventing labour delay 23. Pain relief for preventing delay and reducing the use of augmentation in labour is not recommended. b Not recommended Oral fluid and food 24. For women at low risk, oral fluid (...) and food intake during labour is recommended. b Recommended Maternal mobility and position 25. Encouraging the adoption of mobility and an upright position during labour in women at low risk is recommended. b Recommended Vaginal cleansing 26. Routine vaginal cleansing with chlorhexidine during labour for the purpose of preventing infectious morbidities is not recommended. a Not recommended Active management of labour 27. A package of care for active management of labour for prevention of delay

2018 World Health Organisation Guidelines

120. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

pathways are mechanisms for the human immune system to control the immune response. The immune checkpoint proteins cytotoxic T-lymphocyte–associated-4 (CTLA-4) and programmed cell death protein 1 (PD-1) are receptors expressed on the surface of cytotoxic T cells that interact with their ligands CD80/CD86 in the case of CTLA-4 and programmed death-ligand 1 (PD-L1) in the case of PD-1. These pathways can be co-opted to help cancer cells to evade cytotoxic T-cell–mediated death. ICPis work by preventing (...) medical decisions and improve cancer care and that all patients should have the opportunity to participate. Currently, there are several ICPis approved by the US Food and Drug Administration. Ipilimumab, an anti–CTLA-4 antibody, was the first agent approved for use in patients with advanced melanoma. Pembrolizumab and nivolumab target PD-1 and have been approved for melanoma, metastatic non–small-cell lung cancer (NSCLC), head and neck squamous cancers, urothelial carcinoma, gastric adenocarcinoma

2018 American Society of Clinical Oncology Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>